Earnings Summary on Insperity

Insperity (NSP) reported Q2 2025 results with revenue of $1.70 billion, up 3% year-over-year and exceeding expectations, yet profitability sharply declined as non-GAAP EPS plummeted 70% to $0.26, missing consensus by 36.6%. This significant earnings miss and GAAP net loss were primarily driven by unexpected surges in healthcare benefit costs. Consequently, management significantly reduced full-year 2025 guidance for EPS by 30-49%, signaling continued margin pressure, despite implementing pricing and benefit plan changes aimed at 2026 improvements and ongoing strategic investments in initiatives like the Workday partnership.

Analysis

Insperity's second-quarter results present a stark contrast between resilient top-line performance and a severe collapse in profitability. While revenue grew 3% year-over-year to $1.70 billion, exceeding expectations on the back of a 1% increase in worksite employees, the core issue was a dramatic margin compression. Non-GAAP EPS plummeted 70% to $0.26, missing consensus by 36.6%, and adjusted EBITDA was nearly halved. This was driven almost entirely by an unexpected surge in healthcare benefit costs, specifically from elevated pharmacy trends and large claim activity, which resulted in a GAAP net loss of $5 million. In response, management is implementing pricing and benefit plan adjustments, but these are positioned as a solution for 2026, not the immediate future. The gravity of the situation is underscored by the significant downward revision of full-year 2025 guidance, with adjusted EPS now expected to fall by 30% to 49% and adjusted EBITDA by 24% to 37%. Despite these headwinds, the company is continuing strategic investments, such as the $14 million allocated to its Workday partnership, and maintained its capital return program, returning $64 million to shareholders in the first half of 2025.

Key Decisions for Investors

• Given the severe earnings miss and a drastic 30-49% reduction in full-year EPS guidance, investors should anticipate continued share price pressure until management demonstrates tangible progress in mitigating healthcare cost inflation.
• The primary catalyst for a turnaround is the effectiveness of new pricing and benefit plan changes; monitor subsequent quarterly reports for stabilization in gross margins and any updates on cost trends heading into 2026.
• While long-term growth initiatives like the Workday partnership are positive, the immediate and severe margin compression requires a cautious stance, and the sustainability of the capital return program should be scrutinized given the sharp decline in projected profitability.